Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782139 | 1.00 | PDE5A (0.84) | PDE5A | |
| SCHEMBL6782144 | 1.00 | PDE5A (0.84) | PDE5A | |
| SCHEMBL7714894 | 0.93 | PDE5A (0.86) | PDE5A | |
| SCHEMBL6784109 | 0.93 | PDE5A (0.86) | PDE5A | |
| SCHEMBL7714898 | 0.93 | PDE5A (0.86) | PDE5A | |
| SCHEMBL1326139 | 0.92 | PDE5A (0.85) | PDE5A | |
| SCHEMBL1326138 | 0.92 | PDE5A (0.85) | PDE5A | |
| SCHEMBL1326142 | 0.92 | PDE5A (0.85) | PDE5A | |
| SCHEMBL7433397 | 0.91 | PDE5A (0.84) | PDE5A | |
| SCHEMBL7683497 | 0.91 | PDE5A (0.84) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784179-B2 | treating a vascular disease by administering e.g. tadalafil in combination with an endothelium-derived relaxing factor, an atrial natriuretic factor, a brain natriuretic peptide, a C-type natriuretic peptide, or an endothelium-dependent relaxing agent such as serotonin | ICOS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | ICOS CORPORATION | 2002-08-29 | — | — | US | disclosed |
| US-6369059-B1 | INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP SPECIFIC PDE); CARDIOVASCULAR DISORDERS; PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONES | ICOS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6127542-A | CHEMICAL INTERMEDIATES TO SPECIFIED PYRAZINO(2',1':6,1)PYRIDO(3,4B)INDOLE-1,4-DIONES WHICH ARE SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE; TO TREAT CARDIOVASCULAR DISORDERS | ICOS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-6025494-A | CYCLIZATION OF DICARBONYL-SUBSTITUTED PYRIDOINDOLES YIELDS PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2000-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | PDE3A, PDE3B, PDE2A | PDE5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.